BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26048307)

  • 1. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
    Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
    Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for allosteric interactions of antagonist binding to the smoothened receptor.
    Rominger CM; Bee WL; Copeland RA; Davenport EA; Gilmartin A; Gontarek R; Hornberger KR; Kallal LA; Lai Z; Lawrie K; Lu Q; McMillan L; Truong M; Tummino PJ; Turunen B; Will M; Zuercher WJ; Rominger DH
    J Pharmacol Exp Ther; 2009 Jun; 329(3):995-1005. PubMed ID: 19304771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
    Sinha N; Chowdhury S; Sarkar RR
    Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
    Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
    Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened.
    Tao H; Jin Q; Koo DI; Liao X; Englund NP; Wang Y; Ramamurthy A; Schultz PG; Dorsch M; Kelleher J; Wu X
    Chem Biol; 2011 Apr; 18(4):432-7. PubMed ID: 21513879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
    Peluso MO; Campbell VT; Harari JA; Tibbitts TT; Proctor JL; Whitebread N; Conley JM; White KF; Kutok JL; Read MA; McGovern K; Faia KL
    PLoS One; 2014; 9(3):e90534. PubMed ID: 24608250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
    Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
    Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
    Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
    Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo.
    Wu H; Zhang L; Chen B; Ou B; Xu J; Tian N; Yang D; Ai Y; Chen Q; Quan D; Zhang T; Lv L; Tian Y; Zhang J; Wu S
    Bioorg Chem; 2023 Jun; 135():106488. PubMed ID: 36989734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
    Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
    Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural optimization on a virtual screening hit of smoothened receptor.
    Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
    Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo).
    Zhang X; Harrington N; Moraes RC; Wu MF; Hilsenbeck SG; Lewis MT
    Breast Cancer Res Treat; 2009 Jun; 115(3):505-21. PubMed ID: 18563554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and mechanism of action of the acylguanidine MRT-83, a novel potent Smoothened antagonist.
    Roudaut H; Traiffort E; Gorojankina T; Vincent L; Faure H; Schoenfelder A; Mann A; Manetti F; Solinas A; Taddei M; Ruat M
    Mol Pharmacol; 2011 Mar; 79(3):453-60. PubMed ID: 21177415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Kinetic Binding Properties of Unlabeled Ligands via a Preincubation Endpoint Binding Approach.
    Shimizu Y; Ogawa K; Nakayama M
    J Biomol Screen; 2016 Aug; 21(7):729-37. PubMed ID: 27270099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
    Liao S; Floyd C; Verratti N; Leung L; Wu C
    Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.